# EDGAR Filing Document

**Accession Number:** 0001434265
**File Stem:** 0001434265-25-000050
**Filing Date:** 2025-6
**Character Count:** 15907
**Document Hash:** 17210205b79f083a52df6cb820757802
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001434265-25-000050.hdr.sgml**: 20250623

**ACCESSION NUMBER**: 0001434265-25-000050

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20250623

**FILED AS OF DATE**: 20250623

**DATE AS OF CHANGE**: 20250623

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GENMAB A/S
- **CENTRAL INDEX KEY:** 0001434265
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38976
- **FILM NUMBER:** 251063439

**BUSINESS ADDRESS:**
- **STREET 1:** TOLDBODGADE 33
- **CITY:** 1253 COPENHAGEN K
- **STATE:** G7
- **ZIP:** 00000

**MAIL ADDRESS:**
- **STREET 1:** TOLDBODGADE 33
- **CITY:** 1253 COPENHAGEN K
- **STATE:** G7
- **ZIP:** 00000

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**<br>FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE MONTH OF JUNE 2025**

**COMMISSION FILE NUMBER 001-38976** 

**Genmab A/S**<br> (Exact name of Registrant as specified in its charter)

**Carl Jacobsens Vej 30**

**2500 Valby**

**Denmark**

**+45 70 20 27 28**<br> (Address of principal executive offices)<br>

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| <u>Exhibit</u> | <u>Description of Exhibit</u> |
| 99.1 | <u>[Company Announcement Dated June 23, 2025: Transactions in Connection with Share Buy-back Program](genmab_20250623xxex99d1.htm)</u> |
| 99.1(a) | <u>[Appendix - Share buyback program - specification for June](genmab_20250623xxex99d1a.htm)[16](genmab_20250623xxex99d1a.htm)[-](genmab_20250623xxex99d1a.htm)[20](genmab_20250623xxex99d1a.htm)[, 2025](genmab_20250623xxex99d1a.htm)</u> |

---

------

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| GENMAB A/S | GENMAB A/S |
| BY: | /s/ Anthony Pagano |
| | Name: Anthony Pagano |
| | Title: Executive Vice President & Chief Financial Officer |

---

**DATE: JUNE 23, 2025**

## Exhibit 99.1

**Exhibit 99.1**

![genmab_logo.jpg](genmab_logo.jpg)

**Transactions in Connection with Share Buy-back Program**

**Company Announcement**

**COPENHAGEN, Denmark; June 23, 2025 – Genmab A/S (Nasdaq: GMAB).** On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025.

The following transactions were executed under the program from June 16 to June 20, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Trading Platform | No. of shares | Average price (DKK) | Total value (DKK) |
| **Accumulated through last announcement** |  | **2080711** |  | **2706417889.19** |
| **June 16, 2025** | XCSE | 100 | 1477.73 | 147772.50 |
|  | BCXE | 0 |  |  |
|  | AQEU | 0 |  |  |
|  | TQEX | 0 |  |  |
|  | **Total** | **100** |  | **147772.50** |
| **June 17, 2025** | XCSE | 100 | 1453.09 | 145309.00 |
|  | BCXE | 0 |  |  |
|  | AQEU | 0 |  |  |
|  | TQEX | 0 |  |  |
|  | **Total** | **100** |  | **145309.00** |
| **June 18, 2025** | XCSE | 100 | 1417.26 | 141725.50 |
|  | BCXE | 0 |  |  |
|  | AQEU | 0 |  |  |
|  | TQEX | 0 |  |  |
|  | **Total** | **100** |  | **141725.50** |
| **June 19, 2025** | XCSE | 100 | 1403.98 | 140398.00 |
|  | BCXE | 0 |  |  |
|  | AQEU | 0 |  |  |
|  | TQEX | 0 |  |  |
|  | **Total** | **100** |  | **140398.00** |
| **June 20, 2025** | XCSE | 100 | 1395.62 | 139561.50 |
|  | BCXE | 0 |  |  |
|  | AQEU | 0 |  |  |
|  | TQEX | 0 |  |  |
|  | **Total** | **100** |  | **139561.50** |
| **Total** |  | **500** |  | **714766.50** |
| **Accumulated under the program** | **Accumulated under the program** | **2081211** |  | **2707132656.69** |

---

Details of each transaction are included as an appendix to this announcement.

Following these transactions, Genmab holds 2,532,938 shares as treasury shares, corresponding to 3.95% of the total share capital and voting rights.

Genmab A/S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark Tel: +45 7020 2728<br>www.genmab.com<br> Company Announcement no. 36Page 1/2CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122

------

![genmab_logo.jpg](genmab_logo.jpg)

**Transactions in Connection with Share Buy-back Program**

The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 ('MAR') and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the "Safe Harbour Regulation." Further details on the terms of the share buy-back program can be found in our company announcement no. 14 dated March 25, 2025.

**About Genmab** 

Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines<sup>®</sup>.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit <u>Genmab.com</u> and follow us on <u>LinkedIn</u> and <u>X</u>.<br>

**Contact:&nbsp;&nbsp;&nbsp;&nbsp;**<br> Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs

T: +1 609 524 0065; E: <u>mmp@genmab.com</u>

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: <u>acn@genmab.com</u> 

<br>*The Company Announcement contains forward looking statements. The words "believe," "expect," "anticipate," "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on <u>www.genmab.com</u> and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at <u>www.sec.gov</u>. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.* 

<br>*Genmab A/S and/or its subsidiaries own the following trademarks: Genmab*<sup>®</sup>*; the Y-shaped Genmab logo*<sup>®</sup>*; Genmab in combination with the Y-shaped Genmab logo*<sup>®</sup>*; HuMax*<sup>®</sup>*; DuoBody*<sup>®</sup>*; HexaBody*<sup>®</sup>*; DuoHexaBody*<sup>®</sup>*, HexElect*<sup>®</sup> *and KYSO*<sup>®</sup>*.*

Genmab A/S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark Tel: +45 7020 2728<br>www.genmab.com<br> Company Announcement no. 36Page 2/2CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122

## Exhibit 99.1

**Exhibit 99.1(a)**

![genmab_logo.jpg](genmab_logo.jpg)

APPENDIX Share buy-back programme - Specification for June 16 - 20, 2025

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Issuer | Date | Time CET | Quantity | Price (DKK) | Venue |
| GENMAB A/S | 16-Jun-2025 | 09:35:21 AM | 5 | 1471.00 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 09:35:26 AM | 5 | 1470.00 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 10:11:41 AM | 6 | 1479.50 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 10:50:20 AM | 5 | 1486.00 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 11:27:59 AM | 6 | 1484.00 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 12:20:42 PM | 5 | 1481.00 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 12:54:23 PM | 5 | 1482.00 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 13:50:34 PM | 5 | 1480.50 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 14:35:29 PM | 5 | 1479.00 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 14:51:53 PM | 5 | 1478.50 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 15:19:40 PM | 6 | 1477.50 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 15:32:10 PM | 6 | 1481.50 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 15:39:43 PM | 6 | 1470.50 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 15:50:33 PM | 5 | 1474.00 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 16:01:24 PM | 6 | 1482.50 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 16:19:09 PM | 6 | 1472.00 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 16:29:41 PM | 5 | 1474.50 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 16:45:02 PM | 5 | 1476.00 | XCSE |
| GENMAB A/S | 16-Jun-2025 | 16:49:58 PM | 3 | 1475.00 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 09:28:04 AM | 5 | 1462.00 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 09:28:24 AM | 5 | 1464.00 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 10:03:04 AM | 6 | 1465.50 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 10:38:46 AM | 5 | 1477.50 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 11:21:00 AM | 6 | 1465.00 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 12:10:08 PM | 7 | 1458.50 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 13:04:41 PM | 6 | 1457.50 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 14:04:42 PM | 6 | 1451.00 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 14:47:33 PM | 1 | 1449.50 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 14:47:33 PM | 5 | 1449.50 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 15:20:34 PM | 5 | 1449.50 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 15:31:34 PM | 7 | 1448.50 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 15:39:19 PM | 5 | 1441.00 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 15:49:50 PM | 7 | 1442.00 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 16:00:27 PM | 6 | 1446.50 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 16:19:01 PM | 2 | 1443.50 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 16:19:05 PM | 4 | 1443.50 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 16:34:37 PM | 5 | 1444.00 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 16:49:06 PM | 6 | 1443.50 | XCSE |
| GENMAB A/S | 17-Jun-2025 | 16:54:55 PM | 1 | 1444.00 | XCSE |

---

------

![genmab_logo.jpg](genmab_logo.jpg)

APPENDIX Share buy-back programme - Specification for May 31 – June 4, 2021

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| GENMAB A/S | 18-Jun-2025 | 10:07:05 AM | 5 | 1425.00 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 10:08:11 AM | 5 | 1424.00 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 10:46:44 AM | 5 | 1424.00 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 11:20:21 AM | 5 | 1425.00 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 11:43:32 AM | 5 | 1426.00 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 12:33:10 PM | 6 | 1419.00 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 13:29:20 PM | 6 | 1420.50 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 14:18:01 PM | 5 | 1420.00 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 14:57:31 PM | 5 | 1416.50 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 15:12:21 PM | 5 | 1413.00 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 15:29:59 PM | 5 | 1411.00 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 15:34:27 PM | 7 | 1410.50 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 15:43:59 PM | 6 | 1410.50 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 15:54:30 PM | 5 | 1408.00 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 16:04:12 PM | 5 | 1408.50 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 16:15:49 PM | 5 | 1416.00 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 16:31:20 PM | 7 | 1418.50 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 16:45:20 PM | 5 | 1417.00 | XCSE |
| GENMAB A/S | 18-Jun-2025 | 16:48:22 PM | 3 | 1417.50 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 10:03:50 AM | 5 | 1397.50 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 10:04:34 AM | 5 | 1398.00 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 10:39:08 AM | 5 | 1397.00 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 11:19:17 AM | 7 | 1396.50 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 11:52:01 AM | 6 | 1403.00 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 12:26:20 PM | 5 | 1406.00 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 13:02:13 PM | 3 | 1405.50 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 13:02:13 PM | 2 | 1405.50 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 13:19:34 PM | 5 | 1404.00 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 14:03:49 PM | 6 | 1406.00 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 14:28:33 PM | 5 | 1409.00 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 14:43:32 PM | 7 | 1408.50 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 15:02:29 PM | 5 | 1407.50 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 15:23:17 PM | 6 | 1404.50 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 15:45:35 PM | 7 | 1409.00 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 16:01:14 PM | 5 | 1406.50 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 16:21:11 PM | 5 | 1407.50 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 16:40:49 PM | 6 | 1401.50 | XCSE |
| GENMAB A/S | 19-Jun-2025 | 16:49:31 PM | 5 | 1403.50 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 09:40:30 AM | 5 | 1407.50 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 09:41:51 AM | 5 | 1407.00 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 10:32:09 AM | 6 | 1402.50 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 11:14:09 AM | 6 | 1399.50 | XCSE |

---

------

![genmab_logo.jpg](genmab_logo.jpg)

APPENDIX Share buy-back programme - Specification for May 31 – June 4, 2021

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| GENMAB A/S | 20-Jun-2025 | 11:44:46 AM | 6 | 1400.00 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 11:51:59 AM | 6 | 1399.50 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 12:07:34 PM | 6 | 1397.00 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 12:46:14 PM | 6 | 1396.50 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 13:44:56 PM | 5 | 1398.50 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 14:11:33 PM | 7 | 1398.50 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 14:31:56 PM | 5 | 1400.00 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 14:55:10 PM | 5 | 1398.00 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 14:55:38 PM | 4 | 1398.50 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 14:55:38 PM | 3 | 1398.50 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 15:13:41 PM | 5 | 1396.00 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 15:38:23 PM | 5 | 1385.00 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 16:05:02 PM | 5 | 1378.50 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 16:23:33 PM | 5 | 1380.50 | XCSE |
| GENMAB A/S | 20-Jun-2025 | 16:45:04 PM | 5 | 1371.50 | XCSE |

---